Skip to main content
Lipids in Health and Disease logoLink to Lipids in Health and Disease
. 2022 Apr 6;21:37. doi: 10.1186/s12944-022-01646-6

Correction to: In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model

Antonietta Stellavato 1, Anna Virginia Adriana Pirozzi 1, Francesca de Novellis 1, Ilaria Scognamiglio 1, Valentina Vassallo 1, Andrea Maria Giori 2, Mario De Rosa 1, Chiara Schiraldi 1,
PMCID: PMC8985247  PMID: 35382833

Correction to: Lipids Health Dis 17, 24 (2018)

https://doi.org/10.1186/s12944-018-0663-2

Following the publication of the original article [1], the authors noticed an inaccuracy related to western blotting actin bands in Figs. 5 and 6.

Fig. 5.

Fig. 5

a, b Western blot relative to SOD-2 as a marker of oxidative stress. Actin is used to normalize the results. All values were expressed in the form of mean ± SD (n = 3)

Fig. 6.

Fig. 6

PPARα and PPARγ protein expression levels on HepG2 cells determined by Western blotting. Actin is used to normalize the results

In this respect, the authors apologize for uploading the western blotting (actins bands) that could be misleading. The actins obtained for the filters incubated for SOD-2 antibody were incorrectly duplicated for filters incubated with PPAR-γ. Presented here are the correct Figs. 5 and 6 with the correct actins references.

Reference

  • 1.Stellavato A, Pirozzi AVA, de Novellis F, et al. In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model. Lipids Health Dis. 2018;17:24. doi: 10.1186/s12944-018-0663-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Lipids in Health and Disease are provided here courtesy of BMC

RESOURCES